Brainsway Ltd. has reported a substantial rise in the number of medical policies providing coverage for its SWIFT Accelerated Deep TMS protocol, now reaching over 70 million covered lives in the United States. This update is crucial as it reflects the growing acceptance and integration of innovative mental health treatments into mainstream healthcare.
Founded in 2003, Brainsway is a global leader in advanced noninvasive brain stimulation technologies, specializing in treatments for mental health disorders. The company operates under the SIC code 3841, which pertains to Surgical & Medical Instruments & Apparatus. Brainsway is publicly traded on the Nasdaq and OTC markets under the tickers BWAY and BRSYF, respectively.
The recent filing, dated October 13, 2026, highlights Brainsway's ongoing efforts to expand access to its Deep TMS technology. In a press release accompanying the filing, CEO Hadar Levy stated, "This announcement highlights the increasing pathways toward SWIFT adoption." He emphasized the importance of the growing body of data supporting the efficacy of their accelerated protocol for treating conditions such as major depressive disorder and obsessive-compulsive disorder.
This expansion in coverage is expected to positively impact patients suffering from mental health disorders, as it increases their access to effective treatment options. The favorable policy changes indicate a shift in the healthcare landscape, where innovative treatments are becoming more recognized and accepted.
What's next for Brainsway is not explicitly mentioned in the filing. However, the company continues to engage with stakeholders to promote the benefits of Deep TMS, aiming to further enhance access to these innovative therapies.